AMLX实时信号 | 通过Getagraph.com最大化利润

购买 107419 min ago

@ $15.05

发出时间: 15 Feb 2024 @ 04:52

回报率: -88.31%

上一信号: Feb 15 - 04:25

上一信号: 出售

回报率: -0.69 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases...

Stats
今日成交量	5.22M
平均成交量	3.37M
市值	119.69M
EPS	$0 ( 2024-02-22 )
下一个收益日期	( $0.240 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	2.51
ATR14	$0.00600 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Frates James M	Buy	91 180	Common Stock
2024-04-16	Frates James M	Buy	120 000	Stock Option (right to buy)
2024-04-16	Cohen Joshua B	Buy	179 850	Common Stock
2024-04-16	Cohen Joshua B	Buy	380 000	Stock Option (right to buy)
2024-04-16	Mazzariello Gina	Buy	80 560	Common Stock

INSIDER POWER
25.29
Last 97 transactions
Buy: 3 771 999 \| Sell: 3 035 438

音量相关性

長: -0.18 (neutral)

短: -0.20 (neutral)

Signal:(48.522) Neutral

Amplify YieldShares Oil 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Amplify YieldShares Oil 相关性 - 货币/商品

0.00
( neutral )

0.62
( weak )

-0.01
( neutral )

Amplify YieldShares Oil 财务报表

Annual	2023
营收:	$380.79M
毛利润:	$355.35M (93.32 %)
EPS:	$0.730

FY	2023
营收:	$380.79M
毛利润:	$355.35M (93.32 %)
EPS:	$0.730

FY	2022
营收:	$22.23M
毛利润:	$19.24M (86.54 %)
EPS:	$-2.98

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.592

Financial Reports:

No articles found.

Amplify YieldShares Oil

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.